- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02733926
Effect of Vegetation in Kindergartens on the Immune Response of Children (ADELEWP1t7)
July 16, 2019 updated by: Aki Sinkkonen, University of Helsinki
ADELE: Autoimmune Defense and Living Environment Acronym Description: Adele Comes From the Capitalized Words in the Following Words: Autoimmune DEfense and Living Environment
This study evaluates the effect of vegetation cover on certain Interleukin-10 and immunoglobulinE (IgE) among children (3-5 y old).
Children will either be in a kindergarten that does not have forest floor and agricultural land in the backyards, or alternatively they will be in a kindergarten that does have forest floor and agricultural land in the backyards.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
High vegetation cover is assumed to change immunoglobulinE (IgE) and interleukin-10 concentrations in blood serum.
Children living in high-green kindergarten are compared with those kindergarten living utilizing backyards with a low-green cover.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Häme
-
Lahti, Häme, Finland, 15140
- Helsinki University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 years to 5 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- children living in study kindergartens
Exclusion Criteria:
- immune system deficiency, e.g. HIV-infection
- a drug decreasing immune system response, e.g. oral corticosteroid
- immune system disorder that affects immune response, e.g. rheumatoid
- colitis ulcerosa, Crohn disease, diabetes
- cancer
- age less than 3 or more than 5
- born outside Finland
- intellectual disability
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: City kindergarten
Children living in a normal city kindergarten that hardly has vegetation in backyards
|
|
Experimental: adding of vegetation into the backyards.
Children living in a normal city kindergarten that has plenty of vegetation in backyards. Intervention: adding of vegetation into the backyards. |
Living plants are transferred into the backyards of kindergartens.
This is assumed to affect the measured variables of children.
|
No Intervention: Nature kindergarten
Children living in a city kindergarten where children go regularly into a natural forest
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diversity of Gammaproteobacteria on skin.
Time Frame: 28 days
|
Diversity of skin Gammaproteobacteria is higher in intervention arm compared to control arm and similar compared to nature-oriented arm after 28-day intervention.
It will be measured at baseline and after 28-day intervention.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TGF-beta change in serum plasma
Time Frame: 28 days
|
An increase in TGF-beta in intervention arm but not in control arm at the end of the 28 days intervention
|
28 days
|
TGF-beta: IL-17A ratio in serum plasma
Time Frame: 28 days
|
An increase in TGF-beta: IL17A ratio in intervention arm but not in control arm at the end of the 28 days intervention
|
28 days
|
IL-10 change in serum plasma
Time Frame: 28 days
|
An increase in IL-10 in intervention arm but not in control arm at the end of the 28 days intervention
|
28 days
|
IL-17A change in serum plasma
Time Frame: 28 days
|
A decrease in IL-17A in intervention arm but not in control arm at the end of the 28 days intervention
|
28 days
|
Skin bacterial community changes at phylum level
Time Frame: 28 days
|
Diversity of skin bacterial phyla, particularly Proteobacterial community, is higher in intervention arm compared to control arm.
Proteobacterial community was associated with the coverage of green land cover in an earlier study.
In addition, it was different in atopic and non-atopic study subjects in an earlier study.
Diversity is measured as Shannon diversity index, Multivariate Homogeneity of Group Dispersions and the number of taxa (richness).
|
28 days
|
Skin bacterial community changes at class level
Time Frame: 28 days
|
Diversity of skin bacterial classes is higher in intervention arm compared to control arm.
Diversity of skin bacterial classes is higher in intervention arm compared to control arm.
Other community changes include changes in relative abundance, richness and in community composition.
If community changes are found, the same difference is searched for in the comparison of surface soil microbiota of intervention versus standard daycare yards.
Diversity is measured as Shannon diversity index, Multivariate Homogeneity of Group Dispersions and the number of taxa (richness).
|
28 days
|
Skin bacterial community changes at order level
Time Frame: 28 days
|
Order level diversity is higher in intervention arm than control arm (in standard daycares).
Other community changes include changes in relative abundance, richness and in community composition.
If community changes are found, the same difference is searched for in the comparison of surface soil microbiota of intervention versus standard daycare yards.
|
28 days
|
Skin bacterial community changes at family level are higher in intervention than control arm
Time Frame: 28 days
|
If differences are found, it will be checked if diversity of one or more skin bacterial families is related to soil bacterial diversity.
Diversity is measured as Shannon diversity index, Multivariate Homogeneity of Group Dispersions and the number of taxa (richness).
|
28 days
|
Skin bacterial community changes at genus level
Time Frame: 28 days
|
Diversity of skin bacterial genera is related to arms, i.e. higher in intervention arm.
If differences are found, it will be checked if these occur also in soil bacterial diversity.
Diversity is measured as Shannon diversity index, Multivariate Homogeneity of Group Dispersions and the number of taxa (richness).
|
28 days
|
Stool bacterial community changes at phylum level
Time Frame: 28 days
|
Community composition of gut bacterial phyla are different between arms.
Other changes include changes in relative abundance, richness and diversity.
|
28 days
|
Stool bacterial community changes at class level
Time Frame: 28 days
|
Community composition of gut bacterial classes are different between arms.
Other changes include changes in relative abundance, richness and diversity.
|
28 days
|
Stool bacterial community changes at order level
Time Frame: 28 days
|
Community composition of gut bacterial orders are different between arms.
Other changes include changes in relative abundance, richness and diversity.
|
28 days
|
Stool bacterial community changes at family level
Time Frame: 28 days
|
Community composition of gut bacterial families, particularly Ruminococcaceae, is different between arms.
Ruminococcaceae contain taxa associated with the production of short chain fatty acids, such as butyrate.
Other changes include changes in relative abundance, richness and diversity.
|
28 days
|
Gut Faecalibacterium community changes
Time Frame: 28 days
|
Community composition of gut Faecalibacterium is different between arms.
Faecalibacterium has been associated with gut health and low incidence of certain immune mediated diseases.
|
28 days
|
Associations between serum plasma TGF-beta and skin microbiota changes
Time Frame: 28 days
|
change in the cytokine will be separately compared with changes in bacterial diversity on skin
|
28 days
|
Associations between serum plasma IL-10 and skin Gammaproteobacterial microbiota changes
Time Frame: 28 days
|
change in the cytokine will be separately compared with changes in Gammaproteobacterial diversity on skin
|
28 days
|
Associations between serum plasma IL-17 and skin Gammaproteobacterial microbiota changes
Time Frame: 28 days
|
change in the cytokine will be separately compared with changes in Gammaproteobacterial diversity on skin
|
28 days
|
Interleukin-10 : interleukin-17A ratio in serum plasma
Time Frame: 28 days
|
An increase IL-10: IL-17A ratio in each arm at the end of the 28 day intervention will be examined
|
28 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Associations between IL-10 and stool commensal microbiota
Time Frame: 28 days
|
Associations between serum plasma cytokine IL-10 and gut microbiota changes are related to intervention.
Bacterial communities are related to immune response in one or more arms.
|
28 days
|
Associations between IL-17 and stool commensal microbiota
Time Frame: 28 days
|
Associations between serum plasma IL-17 and gut microbiota changes are related to intervention.
Bacterial communities are related to immune response in one or more arms.
|
28 days
|
Associations between TGF-beta and stool commensal microbiota
Time Frame: 28 days
|
Associations between serum plasma TGF-beta and gut microbiota changes are related to intervention.
Bacterial communities are related to immune response in one or more arms.
|
28 days
|
Associations between IL-10: IL-17 ratio and stool commensal microbiota
Time Frame: 28 days
|
Associations between serum plasma IL-10: IL-17ratios and gut microbiota changes are related to intervention.
Bacterial communities are related to immune response in one or more arms.
|
28 days
|
Associations between TGF-beta: IL-17 ratio and stool commensal microbiota
Time Frame: 28 days
|
Associations between serum plasma TGF-beta: IL-17 ratio and gut microbiota changes are related to intervention.
Bacterial communities are related to immune response in one or more arms.
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Aki Sinkkonen, Docent, University of Helsinki
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2016
Primary Completion (Actual)
June 30, 2018
Study Completion (Anticipated)
December 1, 2019
Study Registration Dates
First Submitted
March 23, 2016
First Submitted That Met QC Criteria
April 5, 2016
First Posted (Estimate)
April 12, 2016
Study Record Updates
Last Update Posted (Actual)
July 17, 2019
Last Update Submitted That Met QC Criteria
July 16, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- HelsinkiU1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Data will be available when the project has ended.
Before it data will be available once the results have been published.
Individual participants or families will not be recognizable in the public data set.
If there is a danger that a person can be recognized, the data will not be made public.
Finnish law and the decision of the ethical committee may limit public availability of data.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ige Responsiveness, Atopic
-
CHU de ReimsCompletedFluid Responsiveness | Preload ResponsivenessFrance
-
Bhumibol Adulyadej HospitalNot yet recruitingFluid Responsiveness
-
Erasme University HospitalUniversité Paris-Saclay-Assistance publique des hôpitaux de ParisCompleted
-
Yonsei UniversityCompletedFluid ResponsivenessKorea, Republic of
-
Second Affiliated Hospital, School of Medicine,...Unknown
-
Institute of Mountain Emergency MedicineDepartment of Anaesthesiology, Merano Hospital, ItalyCompleted
-
Radboud University Medical CenterUnknownFluid ResponsivenessNetherlands
-
Samsung Medical CenterCompletedClopidogrel Non-ResponsivenessKorea, Republic of
-
Seoul National University HospitalNot yet recruitingAnesthesia | Fluid Responsiveness
-
Indonesia UniversityRecruitingHemodynamic Monitoring | Fluid ResponsivenessIndonesia
Clinical Trials on Adding of vegetation into the backyards of kindergarten
-
Cytori TherapeuticsCompletedCoronary Artery Disease | Coronary Disease | Cardiovascular Disease | Ischemic Heart Disease | Coronary ArteriosclerosisSpain, Denmark, Netherlands
-
University of ZurichWithdrawnHepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma | Liver MetastasisSwitzerland
-
Neurologix, Inc.Weill Medical College of Cornell University; North Shore University HospitalCompletedParkinson's DiseaseUnited States
-
Meir Medical CenterThe Trendlines GroupCompleted
-
Hospital Clinic of BarcelonaSociedad Española de Radiologia MedicaCompletedBack Pain | Osteoporosis | Spinal FractureSpain
-
Tan Tock Seng HospitalNanyang Technological University; Woodlands Health CampusCompletedGastrointestinal Diseases | Esophagus Disorder | Enteral and Supplement Feeds Adverse ReactionSingapore
-
Seoul National University HospitalCompletedAdhesive CapsulitisKorea, Republic of
-
Michigan State UniversityCompletedExercise | InsulinUnited States
-
Michael MurphyZimmer BiometCompletedPeripheral Artery Disease | Critical Limb Ischemia | Vascular DiseaseUnited States